Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Zipalertinib in Non-small cell lung carcinoma (NSCLC). The expected timing is based on the latest available company guidance and may change.
REZILIENT3 trial: w/ Taiho Oncology. 8/3/23- Initiated trial. 5/8/25- Enrollment continues. 8/7/25- To complete enrollment by H1 2026. 11/06/25:- Partner expects REZILIENT3 Ph3 enrollment to complete in H1 2026. 03/10/26:- REZILIENT3 Ph3 frontline NSCLC enrollment completed; Taiho expects top-line results by Q4 2026. 05/07/26:- REZILIENT3 Ph3 enrollment completion reiterated; Taiho continues to expect top-line results by end of 2026. 08/06/26:- REZILIENT3 enrollment complete; top-line results expected by end of 2026. 08/12/26:- REZILIENT3 interim analysis met PFS endpoint; unblinding recommended. Full results to be presented at a conference. 08/19/26:- REZILIENT3 interim analysis results to be presented at WCLC on September 14, 2026.
Verification
Confirm timing and program details against the company announcement or filing.